Sponsors (3)
The resolution raises public and research attention to ovarian cancer and hereditary risk—potentially enabling earlier diagnosis and stronger research advocacy—but is largely symbolic without funding or access provisions, so benefits may be limited and could widen disparities in care.
Women and the general public will have increased awareness of ovarian cancer symptoms, which can prompt earlier medical evaluation and potentially earlier diagnosis and treatment.
Women at increased hereditary risk (and their families) will be more likely to be referred for genetic counseling and testing, improving identification of high-risk individuals who could pursue risk-reducing care or surveillance.
Patients with ovarian cancer and cancer researchers benefit from greater attention to research gaps and underfunding, strengthening the case for increased federal research investment into prevention, diagnosis, and treatment.
Taxpayers and patients may see limited practical benefit because the designation is largely symbolic and does not itself provide funding or require policy changes to expand care or research.
Low-income women, women in rural communities, and other underserved groups could face increased unmet demand for genetic testing and specialist care if awareness rises but access and affordability are not improved.
Based on analysis of 2 sections of legislative text.
Designates September 2025 as National Ovarian Cancer Awareness Month to raise awareness about ovarian cancer, hereditary risk, symptom recognition, genetics testing, and research gaps.
Official title: Supporting the designation of September 2025 as "National Ovarian Cancer Awareness Month".
Introduced September 30, 2025 by Rosa L. Delauro · Last progress September 30, 2025
Designates September 2025 as National Ovarian Cancer Awareness Month to increase public awareness about ovarian cancer, promote education about symptoms and hereditary risk, and highlight gaps in screening, research, and care. The resolution summarizes findings about incidence, mortality, survival, racial and geographic disparities, hereditary risk (including BRCA-related risk), low uptake of recommended genetic testing, and underfunding of research relative to mortality.